AbbVie Inc. (NYSE:ABBV) released that TURQUOISE-III study results demonstrating 100% sustained virologic response at 12 weeks post-treatment in genotype 1b (GT1b) chronic hepatitis C virus infected adult patients by means of compensated liver cirrhosis. TURQUOISE-III is a multi-center, open-label Phase 3b study to evaluate the safety and efficacy of 12 weeks […]